Currently, this is the only psychedelic substance that has been legally approved by the FDA for therapeutic purposes.
We anticipate legalization of this medication by 2024. It has shown progress with PTSD, social anxiety, and couples therapy.
Oregon is expected to make this psychedelic available in 2023. It has shown progress with anxiety, depression, and addiction.
If you’re new to psychedelic assisted therapy, here are some articles to help you learn more about it.
MAPS is currently sponsoring MAPP2, the second of two Phase 3 trials to support FDA approval of this breakthrough-designated therapy. In their first Phase 3 study, 88% of participants with severe PTSD experienced a clinically significant reduction in PTSD diagnostic
Depression is the third-leading cause of disability worldwide. Even if successfully treated, however, 80 percent of patients will relapse in the five years following remission. Over 30 percent will fail to respond to at least two antidepressant treatments, and be diagnosed with treatment-resistant
Up to 30% of people with depression don’t respond to treatment with antidepressants. This may be down to differences in biology between patients and the fact that it often takes a long time to respond to the drugs – with some people
Find programs that offer specialized training and certification for licensed clinicians.